Zhenyu Xu - 18 Mar 2026 Form 3 Insider Report for SOPHiA GENETICS SA (SOPH)

Role
Chief Scientific Officer
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu
Issuer symbol
SOPH
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 09:46:18 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Xu Zhenyu Chief Scientific Officer C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND /s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu 18 Mar 2026 0002006362

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SOPH Ordinary Shares 537,724 18 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 10,000 $3.28 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 40,000 $3.17 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 30,000 $4.03 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 40,000 $6.31 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 75,472 $18.00 Direct F3
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 185,874 $4.72 Direct F4
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 251,524 $4.96 Direct F5
holding SOPH Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 187,500 $3.29 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 147,840 ordinary shares have been pledged pursuant to lending arrangements.
F2 Includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 2,704 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 37,833 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 32,027 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
F3 The share options are fully vested and exercisable.
F4 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
F5 The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
F6 The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney